SCHEMBL13611484

SCHEMBL13611484

CCC1CC(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 16/20 0.81
BRD4 O60885 14/20 0.81
BRDT Q58F21 7/20 0.81
PLK3 Q9H4B4 5/20 0.81
ALK Q9UM73 4/20 0.81
PRKD3 O94806 3/20 0.81
CLK2 P49760 3/20 0.81
PTK2 Q05397 3/20 0.81
CAMK2G Q13555 3/20 0.81
CAMK2D Q13557 3/20 0.81
PRKD2 Q9BZL6 3/20 0.81
CSNK1G1 Q9HCP0 3/20 0.81
CSNK1G3 Q9Y6M4 3/20 0.81
TAF1 P21675 3/20 0.81
DAPK3 O43293 2/20 0.81
CHEK2 O96017 2/20 0.81
EGFR P00533 2/20 0.81
FES P07332 2/20 0.81
PHKG2 P15735 2/20 0.81
CSNK1D P48730 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4302288 1.00 PLK1 (0.81) PLK1BRD4BRDTPLK3ALK
SCHEMBL13870847 0.91 BRD4 (0.81) PLK1BRD4BRDTPLK3ALK
SCHEMBL2400870 0.91 BRD4 (0.81) PLK1BRD4BRDTPLK3ALK
SCHEMBL618594 0.91 BRD4 (0.81) PLK1BRD4BRDTPLK3ALK
SCHEMBL4531747 0.91 PLK1 (0.77) PLK1BRD4BRDTPLK3ALK
SCHEMBL1203442 0.90 BRD4 (0.76) PLK1BRD4BRDTPLK3ALK
Bi-2536 SCHEMBL372489 0.89 BRD4 (1.00) PLK1BRD4BRDTPLK3ALK
Bi-2536 SCHEMBL16984416 0.89 BRD4 (1.00) PLK1BRD4BRDTPLK3ALK
SCHEMBL4516762 0.89 PLK1 (0.75) PLK1BRD4BRDTPLK3ALK
Bi-2536 SCHEMBL29395966 0.89 BRD4 (1.00) PLK1BRD4BRDTPLK3ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 US disclosed
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291938-A1 POLO-LIKE KINASE INHIBITORS PLK1, PLK2, POLK PLK1 1/4885BRD4 1323/4885BRDT 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.